MX2022002883A - Combinacion de un poxvirus que codifica para polipeptidos de virus de papiloma humano (vph) e interleucina 2 (il-2) con un anticuerpo anti ligando 1 de muerte programada (pd-l1). - Google Patents
Combinacion de un poxvirus que codifica para polipeptidos de virus de papiloma humano (vph) e interleucina 2 (il-2) con un anticuerpo anti ligando 1 de muerte programada (pd-l1).Info
- Publication number
- MX2022002883A MX2022002883A MX2022002883A MX2022002883A MX2022002883A MX 2022002883 A MX2022002883 A MX 2022002883A MX 2022002883 A MX2022002883 A MX 2022002883A MX 2022002883 A MX2022002883 A MX 2022002883A MX 2022002883 A MX2022002883 A MX 2022002883A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- combination
- poxvirus
- encoding hpv
- poxvirus encoding
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 241000701806 Human papillomavirus Species 0.000 abstract 3
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Abstract
La presente invención se relaciona con una combinación de: a) un vector de poxvirus que codifica para por lo menos los polipéptidos E6 y E7 de virus de papiloma humano (HPV) y una citocina inmunoestimuladora, y b) un anticuerpo anti-PD-L1 o un fragmento del mismo que une antígeno, para usarse en el tratamiento de un cáncer positivo a HPV, en donde una primera administración del poxvirus se realiza 5 a 10 días antes de la primera administración del anticuerpo anti-PD-L1, y se realizan administraciones subsecuentes del poxvirus y del anticuerpo anti-PD-L1.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19306159 | 2019-09-20 | ||
EP20305697 | 2020-06-24 | ||
PCT/EP2020/076232 WO2021053207A1 (en) | 2019-09-20 | 2020-09-21 | Combination of a poxvirus encoding hpv polypeptides and il-2 with an anti-pd-l1 antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022002883A true MX2022002883A (es) | 2022-03-25 |
Family
ID=72659794
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022002883A MX2022002883A (es) | 2019-09-20 | 2020-09-21 | Combinacion de un poxvirus que codifica para polipeptidos de virus de papiloma humano (vph) e interleucina 2 (il-2) con un anticuerpo anti ligando 1 de muerte programada (pd-l1). |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230405105A1 (es) |
EP (1) | EP4031573A1 (es) |
JP (1) | JP2022552090A (es) |
KR (1) | KR20220068242A (es) |
CN (1) | CN114555129A (es) |
AU (1) | AU2020350137A1 (es) |
CA (1) | CA3155090A1 (es) |
IL (1) | IL291427A (es) |
MX (1) | MX2022002883A (es) |
WO (1) | WO2021053207A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MD3472167T2 (ro) | 2016-06-20 | 2023-02-28 | Incyte Corp | Compuși heterociclici ca imunomodulatori |
MX2023005362A (es) | 2020-11-06 | 2023-06-22 | Incyte Corp | Proceso para hacer un inhibidor de proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1) y sales y formas cristalinas del mismo. |
WO2023049831A1 (en) * | 2021-09-24 | 2023-03-30 | Incyte Corporation | Treatment of human papillomavirus-associated cancers by pd-l1 inhibitors |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
KR101607288B1 (ko) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
SG196798A1 (en) | 2008-12-09 | 2014-02-13 | Genentech Inc | Anti-pd-l1 antibodies and their use to enhance t-cell function |
EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
CA2778714C (en) | 2009-11-24 | 2018-02-27 | Medimmune Limited | Targeted binding agents against b7-h1 |
JP6238459B2 (ja) | 2011-08-01 | 2017-11-29 | ジェネンテック, インコーポレイテッド | Pd−1軸結合アンタゴニストとmek阻害剤を使用する癌の治療方法 |
PT2785375T (pt) | 2011-11-28 | 2020-10-29 | Merck Patent Gmbh | Anticorpos anti-pd-l1 e usos destes |
AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
CA2926856A1 (en) | 2013-10-25 | 2015-04-30 | Dana-Farber Cancer Institute, Inc. | Anti-pd-l1 monoclonal antibodies and fragments thereof |
CA2928199A1 (en) | 2013-11-05 | 2015-05-14 | Bavarian Nordic A/S | Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist and/or agonist of an immune checkpoint inhibitor |
CA2935375C (en) | 2014-01-06 | 2023-08-08 | The Trustees Of The University Of Pennsylvania | Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy |
KR102499737B1 (ko) | 2014-05-13 | 2023-02-13 | 버베리안 노딕 에이/에스 | 종양 항원을 발현하는 재조합 폭스바이러스 및 면역 체크포인트 분자 길항제 또는 효현제로 암을 치료하기 위한 복합 요법 |
EP3421046A1 (en) | 2014-11-04 | 2019-01-02 | Janssen Vaccines & Prevention B.V. | Therapeutic hpv16 vaccines |
CN107949397A (zh) | 2015-02-13 | 2018-04-20 | 特兰斯吉恩股份有限公司 | 免疫治疗疫苗和抗体组合治疗 |
KR20180042295A (ko) | 2015-08-20 | 2018-04-25 | 얀센 백신스 앤드 프리벤션 비.브이. | 치료용 hpv18 백신 |
AU2017259259B2 (en) | 2016-05-02 | 2020-11-19 | Bavarian Nordic A/S | Therapeutic HPV vaccine combinations |
-
2020
- 2020-09-21 CA CA3155090A patent/CA3155090A1/en active Pending
- 2020-09-21 EP EP20780977.3A patent/EP4031573A1/en active Pending
- 2020-09-21 AU AU2020350137A patent/AU2020350137A1/en active Pending
- 2020-09-21 US US17/753,943 patent/US20230405105A1/en active Pending
- 2020-09-21 WO PCT/EP2020/076232 patent/WO2021053207A1/en active Application Filing
- 2020-09-21 CN CN202080065400.4A patent/CN114555129A/zh active Pending
- 2020-09-21 KR KR1020227013050A patent/KR20220068242A/ko unknown
- 2020-09-21 JP JP2022517778A patent/JP2022552090A/ja active Pending
- 2020-09-21 MX MX2022002883A patent/MX2022002883A/es unknown
-
2022
- 2022-03-16 IL IL291427A patent/IL291427A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3155090A1 (en) | 2021-03-25 |
US20230405105A1 (en) | 2023-12-21 |
KR20220068242A (ko) | 2022-05-25 |
JP2022552090A (ja) | 2022-12-15 |
AU2020350137A1 (en) | 2022-04-28 |
WO2021053207A1 (en) | 2021-03-25 |
IL291427A (en) | 2022-05-01 |
EP4031573A1 (en) | 2022-07-27 |
CN114555129A (zh) | 2022-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022002883A (es) | Combinacion de un poxvirus que codifica para polipeptidos de virus de papiloma humano (vph) e interleucina 2 (il-2) con un anticuerpo anti ligando 1 de muerte programada (pd-l1). | |
EP4215543A3 (en) | Hpv-specific binding molecules | |
MX2019015477A (es) | Proteinas de union a antigeno del virus del papiloma anti-humano (vph) y metodos de uso de las mismas. | |
MX2020009441A (es) | Metodos para tratar las enfermedades asociadas al vph. | |
PH12020500238A1 (en) | Cytokine conjugates for the treatment of proliferative and infectious diseases | |
MX2020012286A (es) | Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t. | |
EA202190295A1 (ru) | Т-клетки с химерным антигенным рецептором, происходящие от плюрипотентных стволовых клеток, полученных посредством иммуноинженерии | |
MX2019003768A (es) | Moleculas de enlace especificas de hpv. | |
PH12020552229A1 (en) | Il-11ra antibodies | |
MX2020008122A (es) | Anticuerpos anti-pd-1. | |
ZA202105285B (en) | Antibody against human il-4ra and use thereof | |
MX2019010397A (es) | Seleccion de pacientes de cefalea que responden a anticuerpos dirigidos contra el peptido relacionado con el gen de la calcitonina. | |
MX2021001143A (es) | Anticuerpo de union a il-4r humana, fragmento de union a antigeno y uso medico del mismo. | |
MX2020009379A (es) | Anticuerpos. | |
CR20220329A (es) | Anticuerpos anti–mertk y metodos de uso de los mismos | |
WO2017192418A8 (en) | Therapeutic hpv vaccine combinations | |
MX2022014725A (es) | Estrategias de tratamiento del cáncer mediante el uso de vectores de arenavirus. | |
WO2020028719A3 (en) | Compositions comprising herpes simplex virus-1 for use in methods of treating and preventing cancer | |
MX2020008718A (es) | Anticuerpos de union a bcma y usos de los mismos. | |
WO2020180712A8 (en) | Anti-tnfr2 antibodies and uses thereof | |
PH12021551195A1 (en) | Antibodies specifically recognizing granulocyte-macrophage colony stimulating factor receptor alpha and uses thereof | |
MX2020002750A (es) | Anticuerpo il-6r y fragmento de union a antigeno y uso medico. | |
MX2019002382A (es) | Anticuerpos anti-gremlin-1 (grem1) y metodos de uso de los mismos para tratar la hipertension arterial pulmonar. | |
JOP20210247A1 (ar) | علاج الصداع باستخدام أجسام مضادة لـ cgrp | |
AU2019379261A8 (en) | Pharmaceutical combination of anti-CEACAM6 and either anti-PD-1 or anti-PD-l1 antibodies for the treatment of cancer |